Eprodisate is a new compound designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans and thereby inhibit polymerization of amyloid fibrils and deposition of the fibrils in tissues[1]. Eprodisate slow the progression of AA amyloidosis-related renal disease and has possible applicability to other types of amyloidosis[2].
[1]. Dember LM, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007 Jun 7;356(23):2349-60. [2]. Manenti L, et al. Eprodisate in amyloid A amyloidosis: a novel therapeutic approach• Expert Opin Pharmacother. 2008 Aug;9(12):2175-80.